<DOC>
	<DOCNO>NCT00349492</DOCNO>
	<brief_summary>This study randomize , multi-center clinical trial . Patients stratify accord performance status ( ECOG 0 , 1 v 2 ) institution . Patients randomize 1 2 treatment arm . Arm A : Patients receive etoposide IV day 1 , 2 , 3 cisplatin IV day 1 . Courses repeat every 3 week Arm B : Patients receive irinotecan IV day 1 , 8 cisplatin IV day 1 . Coursed repeat every 3 week Treatment arm continue 6 course absence disease progression unacceptable toxicity . Patients follow every 3 month 1.5 year</brief_summary>
	<brief_title>A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin Treat Extensive Disease Small Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Histologically cytologically diagnose small cell lung cancer Extensive disease ( distant metastasis , contralateral hilar lymph node involvement , cytologically confirm malignant pleural effusion ) If patient brain metastasis neurological symptom , stabilize neurologically prior radiotherapy surgery brain metastasis ( neurologic symptom progress without steroid treatment ) No prior chemotherapy , immunotherapy , surgery radiotherapy small cell lung cancer ( Local radiotherapy brain bone metastasis symptom permit , case patient enrol study recover toxicity radiotherapy ) One measurable disease RECIST criterion least 18 year age Performance status 0 , 1 2 Eastern Cooperative Oncology Group ( ECOG ) criteria Adequate hematologic ( neutrophil count &gt; = 1,500/uL , platelet &gt; = 100,000/uL ) , hepatic ( transaminase = &lt; upper normal limit ( UNL ) x2.5 , bilirubin level = &lt; UNLx1.5 ) , renal ( creatinine = &lt; UNL ) function Informed consent patient conforms Institutional Review Board History cure basal cell carcinoma cure uterine cervical malignancy except carcinoma situ within 5 year Medically uncontrolled serious heart , lung , neurological , psychological , metabolic disease Uncontrolled serious infection Enrollment study within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Small Cell Lung Cancer</keyword>
	<keyword>Extensive Disease</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Randomisation</keyword>
</DOC>